Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis

GI Papakostas, NC Salloum, RS Hock… - The Journal of clinical …, 2020 - psychiatrist.com
Objective: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …
被引用次数：88 相关文章

Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis

G Papakostas, N Chaaya Salloum… - The Journal of …, 2020 - dash.harvard.edu
Objective: Esketamine, the s-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …

Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis

GI Papakostas, NC Salloum, RS Hock, MK Jha… - 2020 - psychiatrist.com
Supplementary Material Page 1 © Copyright 2020 Physicians Postgraduate Press, Inc.
Supplementary Material Article Title: Efficacy of Esketamine Augmentation in Major Depressive …

Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis

GI Papakostas, NC Salloum… - The Journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …

Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis

GI Papakostas, NC Salloum, RS Hock… - The Journal of …, 2020 - legacy.psychiatrist.com
Objective: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …

Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.

GI Papakostas, NC Salloum, RS Hock… - The Journal of …, 2020 - europepmc.org
Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-acting
intranasal therapy for depression and is currently under development for suicidality. The …

Efficacy of esketamine augmentation in major depressive disorder: A meta-analysis

GI Papakostas, NC Salloum… - Journal of …, 2020 - utsouthwestern.elsevierpure.com
Objective: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …